EnVVeno Competitors

Stocks . USA . 
Stock . enVVeno Medical Corp
NVNO Stock  USD 10.51  1.18  10.09%   
enVVeno Medical Corp competes with Allurion Technologies, Aethlon Medical, Co Diagnostics, Vivos Therapeutics, and Envoy Medical; as well as few others. The company conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. Analyzing EnVVeno Medical competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of EnVVeno Medical to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out EnVVeno Medical Correlation with its peers.

EnVVeno Medical vs ProPhase Labs Correlation

Very poor diversification

The correlation between enVVeno Medical Corp and PRPH is 0.8 (i.e., Very poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding enVVeno Medical Corp and PRPH in the same portfolio, assuming nothing else is changed.

Moving together with EnVVeno Stock

  0.75SIGL Signal AdvancePairCorr

Moving against EnVVeno Stock

  0.65MRK Merck Company Earnings Call Next WeekPairCorr
  0.64WMT Walmart Common Stock Sell-off TrendPairCorr
  0.57MCD McDonaldsPairCorr
  0.48PFE Pfizer Inc Earnings Call Next WeekPairCorr
  0.47CSCO Cisco Systems Aggressive PushPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
3.1110.5117.91
Details
Intrinsic
Valuation
LowRealHigh
2.6910.0917.49
Details
Naive
Forecast
LowNextHigh
4.7712.1819.58
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
10.4911.8513.22
Details

EnVVeno Medical Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between EnVVeno Medical and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of EnVVeno and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of enVVeno Medical Corp does not affect the price movement of the other competitor.

High positive correlations

PRPH
+ 0.95
GOVX
GOVX
+ 0.94
CODX
PRPH
+ 0.93
AEMD
GOVX
+ 0.91
AEMD
PRPH
+ 0.9
CODX
CODX
+ 0.85
AEMD
  

High negative correlations

GOVX
- 0.86
AYTU
PRPH
- 0.82
AYTU
AYTU
- 0.82
CODX
EKSO
- 0.78
CODX
AYTU
- 0.77
AEMD
GOVX
- 0.7
EKSO

Risk-Adjusted Indicators

There is a big difference between EnVVeno Stock performing well and EnVVeno Medical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze EnVVeno Medical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ALUR  5.54 (0.52) 0.00 (0.04) 0.00 
 0.00 
 16.54 
(10.32)
 40.95 
AEMD  5.76 (0.71) 0.00 (5.26) 0.00 
 0.00 
 10.51 
(10.29)
 38.52 
CODX  6.36 (2.15) 0.00 (0.78) 0.00 
 0.00 
 9.88 
(13.39)
 75.41 
VVOS  3.31 (0.63) 0.00 (0.37) 0.00 
 0.00 
 4.35 
(5.80)
 31.84 
COCH  3.26 (0.31) 0.00 (0.13) 0.00 
 0.00 
 6.94 
(6.17)
 26.25 
EKSO  6.42  1.30  0.21  0.72  5.66 
(7.60)
 10.11 
(9.07)
 112.11 
ADGM  5.57  0.07  0.00  0.01  0.00 
 0.00 
 11.36 
(8.26)
 64.48 
AYTU  2.50  0.37  0.10  0.72  3.08 
(2.60)
 4.69 
(5.26)
 12.75 
GOVX  5.46 (2.45) 0.00 (1.06) 0.00 
 0.00 
 9.38 
(13.70)
 42.89 
PRPH  7.48 (3.79) 0.00 (3.08) 0.00 
 0.00 
 11.11 
(20.00)
 44.34 

EnVVeno Medical Competitive Analysis

The better you understand EnVVeno Medical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, EnVVeno Medical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across EnVVeno Medical's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
NVNO ALUR AEMD CODX VVOS COCH EKSO ADGM AYTU GOVX
 10.09 
 10.51 
EnVVeno
 4.48 
 1.40 
Allurion
 8.23 
 3.01 
Aethlon
 0.33 
 3.00 
CODX
 3.28 
 1.77 
Vivos
 1.49 
 0.68 
Envoy
 9.07 
 7.92 
Ekso
 4.63 
 1.03 
Adagio
 0.74 
 2.72 
Aytu
 6.35 
 2.95 
GeoVax
Market Volatility
(90 Days Market Risk)
Moderately volatile
Abnormally volatile
Dangerous
Extremely Dangerous
Dangerous
Abnormally volatile
Very risky
Out of control
Risky
Dangerous
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Fair
Weakest
Fair
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Risky
Risky
Risky
Moderate
Risky
Risky
Strong
Risky
High
Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Sell
Strong Sell
Cautious Hold
Strong Sell
Cautious Hold
Strong Sell
Current Ratio
20.79
N/A
9.66
16.95
3.15
N/A
8.16
N/A
1.02
9.51
Net Asset
44.95 M
32.81 M
7.36 M
64 M
15.28 M
11.54 M
26.65 M
48.45 M
124.18 M
8.16 M
Profit Margin
N/A
-1.88
N/A
N/A
-0.99
N/A
-0.71
N/A
-0.21
N/A
EBITDA
(21.29 M)
(22.17 M)
(13.04 M)
(38.7 M)
(10.55 M)
(19.81 M)
(9.45 M)
(62.48 M)
(4.67 M)
(24.88 M)
Current Valuation
(22.5 M)
43.71 M
(2.16 M)
(3.71 M)
29.62 M
17.07 M
33.27 M
40.17 M
22.06 M
4.04 M
Price To Book
0.26
N/A
0.56
0.16
7.98
4.22
3.21
3.57
1.19
1.11
Operating Margin
N/A
-3.62
N/A
-48.24
-0.7
-135.9
-0.33
-195.44
-0.11
-7.62
Retained Earnings
(151.85 M)
(222.21 M)
(167.95 M)
(33.04 M)
(104.19 M)
(284.73 M)
(250.47 M)
(70.59 M)
(333.54 M)
(129.36 T)
Current Asset
N/A
N/A
817 K
858.78 K
N/A
N/A
17.57 M
N/A
6.36 M
1.24 M
Beta
1.05
-0.47
1.6
1.26
6.86
2.09
0.71
0.13
0.33
3.68
Number Of Employees
37
134
9
132
262
42
61
80
82
17
Shares Outstanding
655 K
12.28 M
973.21 K
2.1 M
11.42 M
28.93 M
3.56 M
21.18 M
10.19 M
1.73 M
Cash Flow From Operations
(16.84 M)
(42.3 M)
(7.65 M)
(29.16 M)
(12.69 M)
(17.95 M)
(9.85 M)
(29.46 M)
(1.94 M)
(24.68 M)
Total Debt
1.06 M
37.92 M
649.75 K
2.15 M
1.51 M
19.66 M
5.98 M
16.27 M
22.94 M
3.11 M
Return On Equity
-0.57
N/A
-1.91
-0.62
-3.35
N/A
-0.85
-2.1
-0.5
-3.77
Return On Asset
-0.35
-0.72
-0.55
-0.38
-0.5
-1.45
-0.27
-0.24
0.0061
-1.79
Number Of Shares Shorted
2.11 M
444.09 K
20.64 K
2.25 M
282.11 K
480.94 K
1.06 M
327.92 K
513.22 K
1.51 M
Book Value Per Share
50.98
-10.68
7.55
24.82
0.31
-0.32
3.69
-0.085
2.34
4.13
Current Liabilities
N/A
N/A
1.08 M
2.84 M
N/A
N/A
5.51 M
N/A
8.73 M
126.99 K
Total Asset
44.95 M
32.81 M
7.36 M
64 M
15.28 M
11.54 M
26.65 M
48.45 M
124.18 M
8.16 M
Debt To Equity
0.04
N/A
0.047
0.003
0.11
N/A
0.068
N/A
0.47
0.009
Short Ratio
4.79
7.84
0.08
1.19
2.42
2.42
0.19
1.15
5.28
0.44
Target Price
12.5
5.25
12.38
45.0
5.0
7.0
9.5
4.0
9.33
204.63
Shares Owned By Institutions
28.5
54.52
6.76
18.47
11.34
7.83
7.63
68.18
35.65
7.97
Market Capitalization
7.66 M
16.47 M
3.19 M
6.12 M
20.21 M
19.68 M
31.04 M
22.87 M
27.51 M
5.46 M
Price To Earning
N/A
N/A
-1.14
6.78
N/A
N/A
-0.67
N/A
-0.77
-1.25
Price To Sales
N/A
0.96
2.37
12.04
1.17
94.6
2.1
166.96
0.43
1.63
Net Income
(21.82 M)
(26.15 M)
(13.39 M)
(37.64 M)
(11.14 M)
(22.45 M)
(11.33 M)
(75.04 M)
(13.56 M)
(24.99 M)
Earnings Per Share
-37.8
-16.2
209.2
-29.4
-1.77
-1.37
-5.38
-2.46
-2.23
-31.75
Shares Owned By Insiders
9.48
6.37
3.19
5.77
23.48
37.0
15.3
8.0
5.4
0.35
Revenue
N/A
32.11 M
N/A
3.92 M
15.03 M
225 K
17.93 M
269 K
66.38 M
3.95 M
Working Capital
41.64 M
8.29 M
4.05 M
24.98 M
2.5 M
1.85 M
11.31 M
17.59 M
16.11 M
4.83 M
Cash And Equivalents
37.48 M
N/A
14.92 M
86.49 M
17.83 M
N/A
31.91 M
N/A
23.81 M
30.9 M
Cash Per Share
3.96
N/A
0.65
2.8
0.77
N/A
2.45
N/A
0.38
1.25
Gross Profit
N/A
10.5 M
574.25 K
172.84 K
9.65 M
(612 K)
7.89 M
(2.01 M)
43.03 M
(19.38 M)
Day Typical Price
11.01
1.45
3.07
3.04
1.79
0.68
8.43
1.06
2.72
3.06
Accumulation Distribution
3879.14
17987.09
25423.49
1629.7
0.13
1014.67
58316.13
5030.8
3514.92
19844.7
Market Facilitation Index
0.0
0.0
0.0
0.0
0.26
0.0
0.0
0.0
0.0
0.0
Daily Balance Of Power
(0.79)
0.3529
(0.39)
0.037
(0.23)
0.5
(0.50)
(0.50)
0.1818
(0.62)
Period Momentum Indicator
(1.18)
0.06
(0.27)
0.01
(0.06)
0.01
(0.79)
(0.05)
0.02
(0.20)
Rate Of Daily Change
0.9
1.04
0.92
1.0
0.97
1.01
0.91
0.95
1.01
0.94
Day Median Price
11.26
1.48
3.1
3.07
1.8
0.68
8.69
1.07
2.72
3.11
Price Action Indicator
(1.34)
(0.04)
(0.22)
(0.06)
(0.06)
0.005
(1.16)
(0.07)
0.015
(0.26)
Relative Strength Index
37.85
44.29
45.37
27.89
38.63
44.99
55.0
49.94
56.85
27.53
Coefficient Of Variation
(669.08)
(4,337)
(1,071)
(592.12)
(947.74)
(2,434)
925.05
(173,590)
750.23
(351.82)
Mean Deviation
5.39
5.54
5.76
6.36
3.31
3.26
6.42
5.57
2.5
5.46
Jensen Alpha
(1.29)
(0.52)
(0.71)
(2.15)
(0.63)
(0.31)
1.3
0.068
0.3697
(2.45)
Total Risk Alpha
(1.83)
(0.95)
(1.41)
(3.09)
(1.00)
(0.64)
0.1439
(0.85)
0.1053
(3.07)
Sortino Ratio
N/A
N/A
N/A
N/A
N/A
N/A
0.2062
N/A
0.0971
N/A
Downside Variance
N/A
N/A
N/A
N/A
N/A
N/A
44.56
N/A
12.19
N/A
Standard Deviation
7.4
7.88
7.36
11.59
4.9
4.56
13.48
8.64
3.15
8.05
Kurtosis
6.66
1.95
0.7133
13.16
10.86
3.79
37.53
9.43
(0.51)
3.8
Potential Upside
8.13
16.54
10.51
9.88
4.35
6.94
10.11
11.36
4.69
9.38
Treynor Ratio
(0.45)
(0.04)
(5.26)
(0.78)
(0.37)
(0.13)
0.7218
0.0128
0.7215
(1.06)
Maximum Drawdown
41.3
40.95
38.52
75.41
31.84
26.25
112.11
64.48
12.75
42.89
Variance
54.82
62.02
54.18
134.44
24.01
20.78
181.71
74.64
9.93
64.73
Market Risk Adjusted Performance
(0.44)
(0.03)
(5.25)
(0.77)
(0.36)
(0.12)
0.7318
0.0228
0.7315
(1.05)
Risk Adjusted Performance
(0.10)
(0.01)
(0.06)
(0.11)
(0.07)
(0.02)
0.0888
0.0087
0.1055
(0.20)
Skewness
(1.66)
1.1
(0.37)
(1.33)
2.34
1.26
5.44
2.01
(0.31)
(0.48)
Semi Deviation
N/A
N/A
N/A
N/A
N/A
N/A
5.66
N/A
3.08
N/A
Information Ratio
(0.16)
(0.03)
(0.10)
(0.18)
(0.12)
(0.06)
0.1021
(0.01)
0.1076
(0.29)
Value At Risk
(10.09)
(10.32)
(10.29)
(13.39)
(5.80)
(6.17)
(9.07)
(8.26)
(5.26)
(13.70)
Expected Short fall
N/A
N/A
N/A
N/A
N/A
N/A
(7.60)
N/A
(2.60)
N/A
Downside Deviation
N/A
N/A
N/A
N/A
N/A
N/A
6.68
N/A
3.49
N/A
Semi Variance
N/A
N/A
N/A
N/A
N/A
N/A
32.03
N/A
9.51
N/A

EnVVeno Medical Competition Performance Charts

Five steps to successful analysis of EnVVeno Medical Competition

EnVVeno Medical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by enVVeno Medical Corp in relation to its competition. EnVVeno Medical's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of EnVVeno Medical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact EnVVeno Medical's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to enVVeno Medical Corp, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your EnVVeno Medical position

In addition to having EnVVeno Medical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Tech Growth Thematic Idea Now

Tech Growth
Tech Growth Theme
Instruments that are typically traded at high earnings multiples compared to their competitors and other sectors and have been known to drive market cycles frequently. The Tech Growth theme has 57 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tech Growth Theme or any other thematic opportunities.
View All  Next Launch
When determining whether enVVeno Medical Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of EnVVeno Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Envveno Medical Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Envveno Medical Corp Stock:
How To Invest In EnVVeno
Details
Is EnVVeno Stock a good investment?
Details
What is EnVVeno Medical's Net Worth?
Details
Largest Drugs Companies
View
Top Sectors
View
Check out EnVVeno Medical Correlation with its peers.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of EnVVeno Medical. If investors know EnVVeno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about EnVVeno Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of enVVeno Medical Corp is measured differently than its book value, which is the value of EnVVeno that is recorded on the company's balance sheet. Investors also form their own opinion of EnVVeno Medical's value that differs from its market value or its book value, called intrinsic value, which is EnVVeno Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because EnVVeno Medical's market value can be influenced by many factors that don't directly affect EnVVeno Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between EnVVeno Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if EnVVeno Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, EnVVeno Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY